GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (FRA:0ET) » Definitions » Shiller PE Ratio

Esperion Therapeutics (FRA:0ET) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Esperion Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Esperion Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Esperion Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Shiller PE Ratio Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Esperion Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Shiller PE Ratio falls into.



Esperion Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Esperion Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Esperion Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.313/131.7762*131.7762
=0.313

Current CPI (Mar. 2024) = 131.7762.

Esperion Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.442 100.560 -0.579
201409 -0.497 100.428 -0.652
201412 -0.397 99.070 -0.528
201503 -0.517 99.621 -0.684
201506 -0.490 100.684 -0.641
201509 -0.508 100.392 -0.667
201512 -0.532 99.792 -0.703
201603 -0.584 100.470 -0.766
201606 -0.552 101.688 -0.715
201609 -0.686 101.861 -0.887
201612 -1.223 101.863 -1.582
201703 -1.683 102.862 -2.156
201706 -1.709 103.349 -2.179
201709 -1.561 104.136 -1.975
201712 -1.217 104.011 -1.542
201803 -1.403 105.290 -1.756
201806 -1.464 106.317 -1.815
201809 -1.594 106.507 -1.972
201812 -1.969 105.998 -2.448
201903 2.717 107.251 3.338
201906 -1.779 108.070 -2.169
201909 -2.288 108.329 -2.783
201912 -2.034 108.420 -2.472
202003 -2.570 108.902 -3.110
202006 3.836 108.767 4.647
202009 -2.606 109.815 -3.127
202012 -3.198 109.897 -3.835
202103 -2.940 111.754 -3.467
202106 -1.386 114.631 -1.593
202109 -2.227 115.734 -2.536
202112 -1.566 117.630 -1.754
202203 -0.844 121.301 -0.917
202206 -0.993 125.017 -1.047
202209 -0.818 125.227 -0.861
202212 -0.717 125.222 -0.755
202303 -0.738 127.348 -0.764
202306 -0.425 128.729 -0.435
202309 -0.347 129.860 -0.352
202312 -0.458 129.419 -0.466
202403 0.313 131.776 0.313

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Esperion Therapeutics  (FRA:0ET) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Esperion Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (FRA:0ET) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics (FRA:0ET) Headlines

No Headlines